Fluid Resuscitation in Patients Suffering From Burns Injury

PHASE4TerminatedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

December 31, 2012

Primary Completion Date

September 30, 2013

Study Completion Date

September 30, 2013

Conditions
Burns
Interventions
DRUG

Volulyte

6 % hydroxyethyl starch 130/0.4 in an isotonic electrolyte solution will be intravenously infused in order to achieve and maintain predefined hemodynamics goals and may be given up to a total daily dose of 50 mL/kg body weight/day.

DRUG

Human Serum Albumin

5% Human Serum Albumin will be intravenously infused in order to achieve and maintain predefined hemodynamics goals with no daily dose limit.

Trial Locations (1)

B15 2WB

University Hospitals Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Queen Elizabeth Medical Centre, Birmingham

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Fresenius Kabi

INDUSTRY

NCT01689506 - Fluid Resuscitation in Patients Suffering From Burns Injury | Biotech Hunter | Biotech Hunter